EDP-514
Phase 1Small molecule
EDP-514 is one of 46 small molecule programs targeting Chronic Hepatitis B Virus Infection. It is currently in Phase 1.
1
Indications
4
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
82 competitors in Chronic Hepatitis B Virus Infection
#DrugCompanyPhaseTrials
1Tyzeka
NovartisPhase 3
Viread
GSKPhase 3
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Hepsera
Bristol-Myers SquibbPhase 3
PEG-Intron
Merck & Co.Phase 3
Levovir
BBukwang Pharmaceutical
Phase 3
Viread
GileadPhase 2
Vemlidy
GileadPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis B Virus Infection3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EDP-514. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EEnanta Pharmaceuticals, Inc